Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX3KRQ)

• Drug Name: N-hydroxy-2,2-diphenylacetamide Drug Info
• Synonyms: Diphenylacetohydroxamic acid; 4099-51-8; N-Hydroxy diphenylacetamide; CHEMBL396097; NSC44620; benzeneacetamide, n-hydroxy-; A-phenyl-; N-Hydroxydiphenylacetamide; BENZENEACETAMIDE,N-HYDROXY-A-PHENYL-; AC1Q5QC3; SCHEMBL2839032; CTK8I6435; DTXSID10286297; AC1L6390; ZINC4522248; NSC-44620; BDBM50207561; MFCD16314231; AKOS022308585; Diphenylacetohydroxamic acid, &gt

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 239512
  CAS Number: CAS 4099-51-8
  TTD Drug ID: DMX3KRQ

Molecule-Related Drug Atlas

Drug(s) Targeting Histone deacetylase 4 (HDAC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[2]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[2]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[2]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[2]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[2]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[2]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[2]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[2]
PMID29671355-Compound-61	DMXH1G3	N. A.	N. A.	Patented	[2]
PMID29671355-Compound-45a	DM5LYKR	N. A.	N. A.	Patented	[2]

Drug(s) Targeting Histone deacetylase (HDAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[3]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[4]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[5]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[6]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[7]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[8]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[5]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[9]
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[10]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase (HDAC)	TTBH0VX	NOUNIPROTAC	Inhibitor	[1]
Histone deacetylase 4 (HDAC4)	TTTQGH8	HDAC4_HUMAN	Inhibitor	[1]

References

• [1] Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
• [2] HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
• [3] Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
• [4] Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
• [8] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [9] US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
• [10] Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
• [11] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.